List of Tables
Table 1. Global Tumor Necrosis Factor Inhibitor Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Tumor Necrosis Factor Inhibitor Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Tumor Necrosis Factor Inhibitor Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Tumor Necrosis Factor Inhibitor Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Tumor Necrosis Factor Inhibitor Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Tumor Necrosis Factor Inhibitor Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Product Type & Application
Table 12. Global Key Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Tumor Necrosis Factor Inhibitor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitor Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2020-2025)
Table 19. Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2026-2031)
Table 21. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2020-2025)
Table 53. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2026-2031)
Table 54. Global Tumor Necrosis Factor Inhibitor Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Tumor Necrosis Factor Inhibitor Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Type (2020-2025)
Table 59. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Type (2026-2031)
Table 60. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2020-2025)
Table 63. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2026-2031)
Table 64. Global Tumor Necrosis Factor Inhibitor Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Tumor Necrosis Factor Inhibitor Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Application (2020-2025)
Table 69. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Application (2026-2031)
Table 70. AbbVie Inc. Company Information
Table 71. AbbVie Inc. Description and Business Overview
Table 72. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 74. AbbVie Inc. Recent Developments/Updates
Table 75. Amgen Inc. Company Information
Table 76. Amgen Inc. Description and Business Overview
Table 77. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 79. Amgen Inc. Recent Developments/Updates
Table 80. Johnson & Johnson Company Information
Table 81. Johnson & Johnson Description and Business Overview
Table 82. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product
Table 84. Johnson & Johnson Recent Developments/Updates
Table 85. UCB Company Information
Table 86. UCB Description and Business Overview
Table 87. UCB Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. UCB Tumor Necrosis Factor Inhibitor Drug Product
Table 89. UCB Recent Developments/Updates
Table 90. Novartis AG Company Information
Table 91. Novartis AG Description and Business Overview
Table 92. Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Novartis AG Tumor Necrosis Factor Inhibitor Drug Product
Table 94. Novartis AG Recent Developments/Updates
Table 95. Pfizer, Inc. Company Information
Table 96. Pfizer, Inc. Description and Business Overview
Table 97. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 99. Pfizer, Inc. Recent Developments/Updates
Table 100. Merck & Co., Inc. Company Information
Table 101. Merck & Co., Inc. Description and Business Overview
Table 102. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 104. Merck & Co., Inc. Recent Developments/Updates
Table 105. CASI Pharmaceuticals Company Information
Table 106. CASI Pharmaceuticals Description and Business Overview
Table 107. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product
Table 109. CASI Pharmaceuticals Recent Developments/Updates
Table 110. EPIRUS Biopharmaceuticals Company Information
Table 111. EPIRUS Biopharmaceuticals Description and Business Overview
Table 112. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product
Table 114. EPIRUS Biopharmaceuticals Recent Developments/Updates
Table 115. LEO Pharma Company Information
Table 116. LEO Pharma Description and Business Overview
Table 117. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product
Table 119. LEO Pharma Recent Developments/Updates
Table 120. PROBIOMED Company Information
Table 121. PROBIOMED Description and Business Overview
Table 122. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product
Table 124. PROBIOMED Recent Developments/Updates
Table 125. Shanghai Pharmaceuticals Holding Co., Ltd. Company Information
Table 126. Shanghai Pharmaceuticals Holding Co., Ltd. Description and Business Overview
Table 127. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product
Table 129. Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Tumor Necrosis Factor Inhibitor Drug Distributors List
Table 133. Tumor Necrosis Factor Inhibitor Drug Customers List
Table 134. Tumor Necrosis Factor Inhibitor Drug Market Trends
Table 135. Tumor Necrosis Factor Inhibitor Drug Market Drivers
Table 136. Tumor Necrosis Factor Inhibitor Drug Market Challenges
Table 137. Tumor Necrosis Factor Inhibitor Drug Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Tumor Necrosis Factor Inhibitor Drug
Figure 2. Global Tumor Necrosis Factor Inhibitor Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Tumor Necrosis Factor Inhibitor Drug Market Share by Type: 2024 & 2031
Figure 4. Humira Product Picture
Figure 5. Enbrel Product Picture
Figure 6. Remicade Product Picture
Figure 7. Simponi Product Picture
Figure 8. Cimzia Product Picture
Figure 9. Biosimilars Product Picture
Figure 10. Global Tumor Necrosis Factor Inhibitor Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 11. Global Tumor Necrosis Factor Inhibitor Drug Market Share by Application: 2024 & 2031
Figure 12. Rheumatoid Arthritis
Figure 13. Psoriatic Arthritis
Figure 14. Juvenile Idiopathic Arthritis
Figure 15. Crohn’s Disease
Figure 16. Ulcerative Colitis
Figure 17. Others
Figure 18. Global Tumor Necrosis Factor Inhibitor Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Tumor Necrosis Factor Inhibitor Drug Market Size (2020-2031) & (US$ Million)
Figure 20. Global Tumor Necrosis Factor Inhibitor Drug Sales (2020-2031) & (K Units)
Figure 21. Global Tumor Necrosis Factor Inhibitor Drug Average Price (US$/Unit) & (2020-2031)
Figure 22. Tumor Necrosis Factor Inhibitor Drug Report Years Considered
Figure 23. Tumor Necrosis Factor Inhibitor Drug Sales Share by Manufacturers in 2024
Figure 24. Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Manufacturers in 2024
Figure 25. Global 5 and 10 Largest Tumor Necrosis Factor Inhibitor Drug Players: Market Share by Revenue in Tumor Necrosis Factor Inhibitor Drug in 2024
Figure 26. Tumor Necrosis Factor Inhibitor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 27. Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 28. North America Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2020-2031)
Figure 29. North America Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2020-2031)
Figure 30. United States Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Canada Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2020-2031)
Figure 33. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2020-2031)
Figure 34. Germany Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. France Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. U.K. Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Italy Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Russia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2020-2031)
Figure 40. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2020-2031)
Figure 41. China Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Japan Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. South Korea Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. India Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Australia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. China Taiwan Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Indonesia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Thailand Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Malaysia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Latin America Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2020-2031)
Figure 51. Latin America Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2020-2031)
Figure 52. Mexico Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Brazil Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Argentina Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2020-2031)
Figure 56. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2020-2031)
Figure 57. Turkey Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Saudi Arabia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. UAE Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. Global Sales Market Share of Tumor Necrosis Factor Inhibitor Drug by Type (2020-2031)
Figure 61. Global Revenue Market Share of Tumor Necrosis Factor Inhibitor Drug by Type (2020-2031)
Figure 62. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Type (2020-2031)
Figure 63. Global Sales Market Share of Tumor Necrosis Factor Inhibitor Drug by Application (2020-2031)
Figure 64. Global Revenue Market Share of Tumor Necrosis Factor Inhibitor Drug by Application (2020-2031)
Figure 65. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Application (2020-2031)
Figure 66. Tumor Necrosis Factor Inhibitor Drug Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
